Sartorius Kurt, Antwi Samuel O, Chuturgoon Anil, Roberts Lewis R, Kramvis Anna
Hepatitis Virus Diversity Research Unit, School of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa.
The Africa Hepatopancreatobiliary Cancer Consortium (AHPBCC), Mayo Clinic, Jacksonville, FL, United States.
Front Oncol. 2022 May 4;12:891812. doi: 10.3389/fonc.2022.891812. eCollection 2022.
Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.
尽管RNA疗法早期有望成为调节癌症异常信号传导的神奇子弹，但该领域仍在不断发展中。然而，RNA疗法目前已成为治疗病毒性疾病（COVID-19）的现实手段，并为癌症治疗带来了巨大希望。这篇综述论文专门研究RNA干扰作为肝癌的一种治疗选择，并讨论了一系列RNA干扰技术，包括反义寡核苷酸（ASO）、适体、小干扰RNA（siRNA）、核酶、核糖开关和CRISPR/Cas9技术。基于这些RNA干扰的干预措施的应用具体概述为三种主要策略，即抑制血管生成、抑制细胞增殖和促进细胞凋亡。我们还讨论了一些固有的化学和递送问题，以及靶向问题和对RNA干扰干预的免疫反应。
